← Oncology Approval Tracker

FDA DECISION ·

Tecelra

afamitresgene autoleucel · Adaptimmune

Accelerated approvalNew therapySynovial sarcoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with unresectable or metastatic synovial sarcoma after chemotherapy, with HLA-A*02:01P, 02:02P, 02:03P or 02:06P and tumor MAGE-A4 expression on authorized companion tests.

LAMPGEN ANALYSIS

Why it matters

This engineered T-cell receptor therapy made cellular treatment available for a biomarker-defined subset of synovial sarcoma.

What research teams should watch

Align HLA typing, MAGE-A4 testing, leukapheresis and product delivery; each can affect whether the treatment window is feasible.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

HLA- and antigen-selected synovial sarcoma

PRIMARY RECORDS

Sources